Prebiotic Fiber as a Modifier of Satiety Hormones and Body Weight in Overweight and Obese Adults

Not Applicable

Completed

• Conditions: Obesity
• Interventions: Dietary Supplement: Oligofructose; Dietary Supplement: Placebo

• Registration Number: NCT00522353
• Lead Sponsor: University of Calgary

Brief Summary

The purpose of this study is to determine if oligofructose supplementation promotes weight loss in overweight and obese adults.

Detailed Description

Obesity is a primary health concern for many western countries as it is linked to several chronic diseases as well as, large health care costs. Although obesity is a multifactorial disease, it is known that levels of satiety hormones including glucagon like peptide-1 (GLP-1) and peptide YY (PYY) are reduced in obesity. The ability of prebiotic fiber to promote weight loss through the production of satiety hormones has been tested previously using rodents. Here it was found that prebiotic supplementation resulted in a decreased energy intake, higher GLP-1 levels in the plasma and increased proglucagon mRNA levels in the gut. This study will address the important question of whether prebiotic fiber supplementation is effective in reducing body weight in overweight or obese human subjects.

Study Timeline

• Study Start: 2007-01
• Primary Completion: 2007-05
• Study Completion: 2007-08
• Study First Submitted: 2007-08-27
• Study First Submitted QC: 2007-08-27
• Study First Posted: 2007-08-29
• Status Verified: 2008-05
• Last Update Submitted: 2008-05-21
• Last Update Posted: 2008-05-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

• overweight or class I obese individuals with BMI between 25 kg/m2 and 34.9 kg/m2
• stable body weight in previous 3 months

Exclusion Criteria

• Type 1 and Type 2 diabetes
• clinically significant cardiovascular abnormalities
• liver or pancreas disease
• major gastrointestinal surgeries
• are pregnant or lactating
• exhibit alcohol or drug dependence
• on drugs influencing appetite
• are following a diet or exercise regime designed for weight loss
• have a body mass greater than 350lb
• chronic use of antacids or bulk laxatives

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	Oligofructose	Oligofructose
2	Placebo	Placebo

Primary Outcome Measures

Name	Time	Method
Body weight	3 months

Secondary Outcome Measures

Name	Time	Method
Plasma satiety hormones	3 months

Trial Locations

Locations (1)

Faculty of Kinesiology, Roger Jackson Centre for Health and Wellness Research; 🇨🇦 Calgary, Alberta, Canada